Prevalence and patient risk factors for pneumothorax in COVID-19 and in influenza pneumonia: a nationwide comparative analysis

Chandna, Sanya; Raj, Kavin; Agrawal, Ankit; Nanda, Saumya; Pillai, Keerthana Jyotheeswara; Bhagat, Umesh; Bajaj, Suryansh; Raoof, Suhail; Mehta, Atul C.

doi:10.21037/jtd-23-1454

J Thorac Dis

2024

DOI: 10.21037/jtd-23-1454

|View full text |Cite

Prevalence and patient risk factors for pneumothorax in COVID-19 and in influenza pneumonia: a nationwide comparative analysis

Sanya Chandna,

Kavin Raj,

Ankit Agrawal

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The Risk of Pneumothorax With Intrapleural Urokinase in Children With Parapneumonic Effusion

Kadmon,

Schoen,

Nahum

et al. 2024

Pediatric Pulmonology

View full text Add to dashboard Cite

AimFibrinolytic therapy is commonly used in children with parapneumonic effusion, to facilitate drainage of the effusions and recovery. However, data regarding complications of this treatment in children are limited. We aimed to determine the incidence of pneumothorax (PNX) associated with intrapleural urokinase.MethodsWe analyzed retrospectively collected data of children with parapneumonic effusion who underwent chest drain insertion. The clinical course and complications, including the incidence of PNX, were compared between children who were and were not treated with urokinase.ResultsThe study group included 120 children, of whom 57 were treated with urokinase. Children who were and were not treated with urokinase did not differ in markers of disease severity or in the length of hospitalization. Among the patients treated with urokinase compared to those not treated, the incidence of PNX was higher (35% vs. 6%, p < 0.001) and the median duration of chest drain treatment was longer (6 vs. 4 days, p < 0.001).ConclusionIn our pediatric cohort, intrapleural urokinase was associated with a higher incidence of PNX and did not shorten the duration of hospitalization.

show abstract

The Risk of Pneumothorax With Intrapleural Urokinase in Children With Parapneumonic Effusion

Kadmon,

Schoen,

Nahum

et al. 2024

Pediatric Pulmonology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Prevalence and patient risk factors for pneumothorax in COVID-19 and in influenza pneumonia: a nationwide comparative analysis

Cited by 1 publication

References 30 publications

The Risk of Pneumothorax With Intrapleural Urokinase in Children With Parapneumonic Effusion

The Risk of Pneumothorax With Intrapleural Urokinase in Children With Parapneumonic Effusion

Contact Info

Product

Resources

About